MyoKardia
Jun 08, 2020
With the Advances in Regenerative Therapy to Offer Curated Treatment Options, Off-label Therapy Market is Set to Decline for Dilated Cardiomyopathy
The Dilated Cardiomyopathy Market Size in the 7MM is expected to increase at a CAGR of 13.1% for the study period 2017-30. Dilated Cardiomyopathy (DCM) is one of the most common types of cardiomyopathies, i.e., diseases of heart muscles. Dilated Cardiomyopathy is a disease that results from the stretching and e...
Read More...
May 12, 2020
Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott’s COVID-19 diagnostic kit
MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...
Read More...
Aug 08, 2017
Cannabidiol trial; MyoKardia aims; LDL drug data
Failure of Phase II cannabidiol trial leads to loss for Zynerba Zynerba Pharmaceuticals’ phase II trial for transdermal cannabinoid candidate missed all its endpoints, as it failed to hit a single goal or show a dose response raises big doubts about the drug's prospects. This news eroded around 55% off Zynerba’s sto...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
